09.01.2013 - Swiss Debiopharm Group (Lausanne) has licenced Chugai’s preclinical anti-cancer agent FF284.
The Tokyo-based Roche affiliate announced the deal on 8 January 2013, three weeks after the companies signed an agreement giving Debiopharm global rights to develop and commercialise the preclinical compound FF284 (now Debiopharm 1347). Chugai remain the rights to the Japanese market.
Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284 (Debio 1347). According to the terms of the agreement, Debiopharm and the Roche daughter will conduct a Phase I dose escalation study. In return for the license, Chugai will receive an undisclosed upfront fee, milestone and royalty payments from Debiopharm.
Debio 1347 is an orally available small molecule targeting an undisclosed signalling pathway affecting solid tumour development
16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.
10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.
05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.
03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.